NCT04689802 To Identify Potential New Urine Marker Panel for Cancer Screening
| NCT ID | NCT04689802 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2021-01-20 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2021-01-20 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Polyamines are naturally produced metabolites in our cells. There were some reports suggested the urinary levels of polyamines were altered in patients with different cancers. This study is to explore the use of urinary polyamine for the diagnosis of common cancers.
Eligibility Criteria
Inclusion Criteria: 1. Adult patients with age \> 18 years old. 2. For cancer patients, a histological diagnosis of cancer is available. 3. For normal control, there is no diagnosis of cancer in the medical record. Exclusion Criteria: 1. Patient with recent urinary tract infection within 6 weeks prior to urine collection. 2. Patient with recent urethral instrumentation, such as Foley catheter insertion, cystoscopy etc, within 6 weeks prior to urine collection. 3. Patient refused or unable to provide consent for the study
Contact & Investigator
Chi Fai Ng, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT04689802 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04689802 currently recruiting?
Yes, NCT04689802 is actively recruiting participants. Contact the research team at ngcf@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT04689802 trial being conducted?
This trial is being conducted at Shatin, Hong Kong.
Who is sponsoring the NCT04689802 clinical trial?
NCT04689802 is sponsored by Chinese University of Hong Kong. The principal investigator is Chi Fai Ng, MD at Chinese University of Hong Kong. The trial plans to enroll 2,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.